Avanir Pharmaceuticals, Inc. introduced the joining of the first affected person in study AVR-131. The research is a Phase II clinical trial examining the use of AVP-923 for the remedy for agitation in affected individuals with Alzheimer's disease.
"Alzheimer's illness can cause any human being to exhibit noticeable personality changes that are testing for caregivers to supervise These indications may include agitation, hostility, anger, and aggression, with the majority of affected individuals exhibiting some or all of these indications during the program of the disease," said Jeffrey Cummings, MD, Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic.
"As the disorder progresses, behavioral indications often increase in frequency and intensity. With no given approval therapies for distress linked to dementia, managing these indications can be demanding. This trial is a vital initial step in potentially giving a therapy to help maintain indicators of agitation in Alzheimer's disease."
The targets of this proof of concept explore are to evaluate the security, tolerability, and performance of AVP-923 for the treatment of anxiety in Alzheimer's affected individuals. The trial is a multicenter, randomized, double-blind, placebo-controlled study that would be expected to register up to 200 Alzheimer's affected individuals in the United States.